Compare Adaptive Biotechnologies Corp (ADPT) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Manhattan Associates Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Manhattan Associates Inc trades at $154.92 (market cap $9.37B). The key difference: Manhattan Associates Inc is far larger — about 2.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MANH | |
|---|---|---|
Market Cap | $3.33B | $9.37B |
Sector | Health | Technology |
52-Week High | $22.37 | $227.94 |
52-Week Low | $10.24 | $120.88 |
Enterprise Value | $3.19B | $9.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MANH trades at $153.81, up 1.83% today, with a bullish technical outlook supported by moving averages and strong support at $150. The company demonstrates robust profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. However, valuation ratios appear elevated with a P/E of 43.1, while ongoing legal investigations pose sentiment risks.
The stock offers upside to the $192.80 consensus price target but faces headwinds from high valuation multiples and legal uncertainties. Earnings growth and cloud strategy execution remain key catalysts, though investors must weigh these against potential dilution from the fiduciary duty investigations highlighted repeatedly in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
